Cystic fibrosis heterozygotes do not have increased platelet activation
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Cystic fibrosis heterozygotes do not have increased platelet activation. / Tarnow, Inge; Michelson, Alan D.; Frelinger III, Andrew L.; Linden, Matthew D.; Li, Youfu; Fox, Marsha L.; Barnard, Marc R.; O'Sullivan, Brian P.
I: Thrombosis Research, Bind 121, Nr. 2, 2007, s. 159-162.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Cystic fibrosis heterozygotes do not have increased platelet activation
AU - Tarnow, Inge
AU - Michelson, Alan D.
AU - Frelinger III, Andrew L.
AU - Linden, Matthew D.
AU - Li, Youfu
AU - Fox, Marsha L.
AU - Barnard, Marc R.
AU - O'Sullivan, Brian P.
PY - 2007
Y1 - 2007
N2 - Introduction: We have previously demonstrated platelet hyperreactivity in cystic fibrosis (CF) patients. Carriers of one CF m utation (heterozygotes) have been shown to have abnormalities related to the presence of only one-half the normal amount of CF transmembrane conductance regulator protein. Platelet hyperreactivity in CF heterozygotes would be an important cardiovascular risk factor, since approximately 1 in 25 Caucasians is a CF carrier.Materials and methods: We used highly sensitive assays of platelet activation to assess the difference between 16 CF heterozygotes and 16 age- and sex-matched healthy controls without CF mutations.Results: We found no difference in platelet activation between CF heterozygotes and controls.Conclusions: The 50% reduction in the CF transmembrane conductance regulator protein in heterozygotes is insufficient to cause platelet activation.
AB - Introduction: We have previously demonstrated platelet hyperreactivity in cystic fibrosis (CF) patients. Carriers of one CF m utation (heterozygotes) have been shown to have abnormalities related to the presence of only one-half the normal amount of CF transmembrane conductance regulator protein. Platelet hyperreactivity in CF heterozygotes would be an important cardiovascular risk factor, since approximately 1 in 25 Caucasians is a CF carrier.Materials and methods: We used highly sensitive assays of platelet activation to assess the difference between 16 CF heterozygotes and 16 age- and sex-matched healthy controls without CF mutations.Results: We found no difference in platelet activation between CF heterozygotes and controls.Conclusions: The 50% reduction in the CF transmembrane conductance regulator protein in heterozygotes is insufficient to cause platelet activation.
KW - Former LIFE faculty
KW - Platelets
KW - Cystic fibrosis
KW - Flow cytometry
KW - Cystic fibrosis carriers
KW - Platelet function
U2 - 10.1016/j.thromres.2007.04.004
DO - 10.1016/j.thromres.2007.04.004
M3 - Journal article
C2 - 17532368
VL - 121
SP - 159
EP - 162
JO - Thrombosis Research
JF - Thrombosis Research
SN - 0049-3848
IS - 2
ER -
ID: 8094892